MPLT Stock - MapLight Therapeutics, Inc.
Unlock GoAI Insights for MPLT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Gross Profit | $-701,000 | $-556,000 | $-574,000 |
| Gross Margin | N/A | N/A | N/A |
| Operating Income | $-82,946,000 | $-57,282,000 | $-31,245,000 |
| Net Income | $-77,580,000 | $-55,709,000 | $-30,016,000 |
| Net Margin | N/A | N/A | N/A |
| EPS | $-1.87 | $-1.34 | $-0.72 |
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 21st 2025 | Morgan Stanley | Initiation | Overweight | $34 |
| November 21st 2025 | Stifel | Initiation | Buy | $28 |
| November 21st 2025 | Jefferies | Initiation | Buy | $32 |
| November 21st 2025 | Leerink Partners | Initiation | Outperform | $30 |
Earnings History & Surprises
MPLTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 5, 2026 | $-1.05 | — | — | — |
Q4 2025 | Dec 4, 2025 | $-1.72 | $-37.18 | -2061.6% | ✗ MISS |
Latest News
SandboxAQ And MapLight Therapeutics Collaborate To Discover And Develop Therapies Targeting G Protein-Coupled Receptor For Treatment Of Central Nervous System Disorders
📈 PositiveMapLight Therapeutics Q3 EPS $(37.18) Misses $(1.55) Estimate
📉 NegativeJefferies Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $32
📈 PositiveLeerink Partners Initiates Coverage On MapLight Therapeutics with Outperform Rating, Announces Price Target of $30
📈 PositiveStifel Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $28
📈 PositiveMorgan Stanley Initiates Coverage On MapLight Therapeutics with Overweight Rating, Announces Price Target of $34
📈 PositiveMapLight Therapeutics IPO Quoting $18.07/Share; IPO Priced At $17/Share On 14.75M Shares
📈 PositiveMapLight Therapeutics IPO Quoting $19.50/Share; IPO Priced At $17/Share On 14.75M Shares
📈 PositiveMapLight Therapeutics IPO Quoting $27.50/Share On 170K Shares; IPO Priced At $17/Share On 14.75M Shares
📈 PositiveTrading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation
➖ NeutralReported Sunday, MapLight Therapeutics Prices 14.75M Share Initial Public Offering At $17 Per Share With Additional 476,707 Shares Sold In Private Placement
📈 PositiveFrequently Asked Questions about MPLT
What is MPLT's current stock price?
What is the analyst price target for MPLT?
What sector is MapLight Therapeutics, Inc. in?
What is MPLT's market cap?
Does MPLT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MPLT for comparison